OncoMatch/Clinical Trials/NCT04136886
Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma
Is NCT04136886 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Cisplatin for nasopharyngeal carcinoma.
Treatment: Cisplatin — The purpose of this study is to determine whether concurrent chemotherapy and IMRT is effective in the treatment of locally stage T3/T4 recurrent nasopharyngeal carcinoma patients compared with IMRT alone.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage RT3, RT4
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: radiation therapy — first course
More than 1 year from the end of the first course of radiotherapy
Cannot have received: anti-tumor treatment
Prior anti-tumor treatment after diagnosis of local recurrence
Lab requirements
Blood counts
WBC count ≥4×10^9/L, neutrophile granulocyte count ≥1.5×10^9/L, PLT count ≥100×10^9/L, Hb ≥9g/L
Kidney function
creatinine ≤ 1.5 times of upper normal limits
Liver function
Total bilirubin, AST, ALT ≤ 2.0 times of upper normal limits
WBC count ≥4×10^9/L, neutrophile granulocyte count≥1.5×10^9/L, PLT count ≥100×10^9/L, Hb ≥9g/L; Total bilirubin, AST, ALT≤2.0 times of upper normal limits; creatinine ≤1.5 times of upper normal limits
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify